Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6518712 | 0.88 | KIF11 (0.54) | KIF11 | |
| SCHEMBL6513048 | 0.82 | KIF11 (0.53) | KIF11 | |
| SCHEMBL6513052 | 0.82 | KIF11 (0.52) | KIF11 | |
| SCHEMBL5103375 | 0.82 | KIF11 (0.69) | KIF11 | |
| SCHEMBL5899009 | 0.77 | KIF11 (0.72) | KIF11 | |
| SCHEMBL12393605 | 0.75 | KIF11 (0.77) | KIF11 | |
| SCHEMBL5106855 | 0.75 | KIF11 (0.65) | KIF11 | |
| SCHEMBL5763171 | 0.74 | KIF11 (0.62) | KIF11 | |
| SCHEMBL5106879 | 0.74 | KIF11 (0.71) | KIF11 | |
| SCHEMBL6515882 | 0.73 | KIF11 (0.38) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509507-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20050234080-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J | 2005-10-20 | — | — | US | disclosed |
| EP-1509507-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003099211-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234080-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIFC1 | KIF11 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.